Corvus Pharmaceuticals, Inc. (CRVS) Misses Q4 EPS by 6c

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q4 EPS of ($0.18), $0.06 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.

You May Also Be Interested In

• Walmart to pay $1.4 billion for Vibe.co acquisition - WSJ
• Varonis Said To Weigh Sale After Takeover Interest - Bloomberg
• Italy's Meloni seeks to normalize US relations after Trump spat